Tag: Thomas Knittel

Company News: InDex Pharmaceuticals to present results from the COLLECT trial at the 10th Congress of the European Crohn’s and Colitis Organisation

InDex Pharmaceuticals today announced that results from COLLECT, a clinical study of the toll-like receptor 9 (TLR9) agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis, will be subject to an oral presentation at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). The congress is to be held in Barcelona, Spain on February 18-21, 2015.

In the COLLECT study, 131 patients with moderate to severe Ulcerative Colitis and inadequate response to conventional therapy received either Kappaproct or placebo as an add-on to conventional treatment. The study was conducted at 40 sites in seven European countries.

Despite not meeting the primary endpoint of inducing clinical remission measured at week 12, defined by a clinical activity index (CAI) score of ≤4, Kappaproct showed statistically significant improvement on important secondary endpoints at week 4 and 8, including symptomatic remission (blood in stool, number of stools) and registration remission (clinical remission with concurrent endoscopic remission) as well as rate of colectomy at week 22. Kappaproct was well tolerated and no safety signals compared to the standard of care treatment group were evident. The data strongly support continued development of Kappaproct as a promising and well-tolerated novel therapeutic option for refractory ulcerative colitis patients. The next phase III study is planned to start this year.

The presentation (Oral presentation #15) titled “Multicentre clinical trial with topical administration of the Toll-Like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis” will be held by Professor Raja Atreya from the University of Erlangen-Nürnberg on Friday, February 20th, 2015, at 14.20pm CET.

Company News: InDex Pharmaceuticals Expands Management Team

– InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer –

Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas Knittel as Chief Medical Officer. Pernilla Sandwall will lead the company’s clinical development team, with the main focus being the ongoing phase III clinical trial of Kappaproct® in patients with treatment-refractory ulcerative colitis. Thomas Knittel will serve as the company’s lead medical expert and provide leadership in medical and marketing affairs.

Pernilla Sandwall has more than 20 years of experience in clinical research operations. She joins InDex Pharmaceuticals from Merck & Co. Inc. (MSD), where she has worked both in the Swedish subsidiary and the U.S. headquarters, as well as regionally in Europe. She has experience in the field as CRA and project manager, as well as strategically as Clinical Research Manager. Her focus over the last years has been global patient recruitment, site selection strategies and execution. She also has experience in change management and Lean Six Sigma methodology.  She has a Master of Science in Pharmacy from Uppsala University.

Thomas Knittel has over 15 years of clinical experience within gastroenterology as well as 13 years of experience in medical affairs and marketing management. Before joining InDex Pharmaceuticals, he held positions as Business Unit Director and Director of Sales and Marketing at Novo Nordisk for central Europe, as General Manager Pharmaceuticals at Harlan Laboratories, and as Vice President Corporate and Medical Affairs at Develogen AG. He has a Medical degree from the University of Mainz with a specialist training in internal medicine and gastroenterology. He is an Associate Professor in Internal Medicine and Gastroenterology at the University Clinic Goettingen. In addition, he has an MBA from Kellogg School of Management/WHU.